Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

Eligibility Criteria

• 1. Biopsy-proven relapsed or progressive diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma, grade 3B follicular lymphoma, or DLBCL arising from indolent lymphoma meeting an FDA-approved (Food and Drug Administration-approved) indication for liso-cel infusion
• 2. Presence of disease on imaging including at least one disease site safe for radiation as determined by treating radiation oncologist
• 3. Willingness to participate in clinical trial and provide informed consent
• 4. Adequate organ function as assessed by standard institution protocols and United States (US) prescribing information label for comorbidities, heart, and lung function to undergo FDA-approved CAR T-cell therapy as determined by institution
• 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• 6. Age 19 years or older, there is no upper limit to the age
• 1. Subject is unsafe for radiation therapy as determined by investigator and/or radiation oncologist
• 2. Diagnosis is primary central nervous system (CNS) lymphoma (secondary CNS lymphoma with additional systemic site is allowed)
• 3. Requirement for concurrent high dose methotrexate
• 4. Secondary active malignancy that has not been in remission for at least 2 years. This excludes non-melanoma skin cancer, definitively treated stage 1 solid tumor with low risk or recurrence, and curatively treated localized prostate cancer.
• 5. Pregnant or nursing women
• 6. Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as determined by investigator
• 7. Unwillingness to follow procedures required in the protocol
• 8. Inadequate organ or hematologic conditions that prohibit the use of lymphodepleting chemotherapy
• 9. Use of lymphoma-directed therapy within 14 days of T-cell pheresis